Latest response from the Iranian side regarding Iran-U.S. negotiations: No decision has been made yet on whether to participate
According to Svmuu, an Iranian source familiar with the matter who participated in the first round of Iran-U.S. negotiations stated that as of 3:00 p.m. local time on the 20th (7:30 p.m. Beijing time), Iran harbors "deep mistrust" toward the U.S. due to the latter’s constantly shifting words and actions. and has not yet decided whether to participate in the second round of Iran-U.S. negotiations. The source noted that the U.S. attack on an Iranian merchant ship on the 19th has further complicated the situation. (CCTV News)
Source:Odaily · Source Link
Disclaimer: This content reflects only the author’s personal views and does not constitute any investment or financial advice. If you discover any content that violates regulations,Click to Report
24H Trending
-
1
Billionaire investor Chase Coleman’s Tiger Global fund disclosed in its latest 13F filing that its top five growth stocks are all focused on AI infrastructure, including TSMC, NVIDIA, Amazon, Meta, and Google.
-
2
Liquidity Crunch in Cryptocurrency Mining: Causes and Analysis of the Current Situation in 2026
-
3
Analysis of CRYSTAL’s Value and Investment Potential: An Examination of Multiple Projects and Risk Assessment
-
4
Will the BEAM token go to zero? Could it rise to $1,000? An in-depth analysis of the Beam network and its market prospects
-
5
The analysis points out that Iran’s overlapping centers of power complicate efforts to end the war with the United States, and that the Revolutionary Guards possess significant operational autonomy.
-
6
Israeli West Bank Settler Tells BBC Attacks on Palestinians Are Justified as Revenge, Equating One Jewish Life to "10 Million" Palestinians
-
7
ETH2X-FLI-P: An Analysis of the 2x Leveraged Ethereum Index Token on Polygon
-
8
What Is CVP? An In-Depth Analysis of the PowerPool Ecosystem and the Investment Value of Its Token, CVP
-
9
Analysis: The State Street Healthcare ETF (XLV) has an expense ratio of 0.08% and a diversified portfolio, while the Invesco Biotechnology ETF (PBE) has an expense ratio of 0.58% and focuses on small-cap stocks; PBE is up 10.2% year-to-date, outperforming XLV.
-
10
Coldcard Wallet Incident Bitcoin: Estimated Losses Rise to $70 Million
Markets Today
Recommended Reading







